Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine potential anti-dyskinetic properties of CPL500036
(PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia.
The study is to determine the efficacy and dose response of two CPL500036 doses, compared
with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Celon Pharma SA
Collaborator:
National Center for Research and Development, Poland